Apelin Receptor Modulation Therapy

therapeutic

Apelin Receptor Modulation Therapy

Overview

flowchart TD
    Apelin_Receptor_Modulation_The["Apelin Receptor Modulation Therapy"]
    Apelin_Receptor_Modulation_The["Therapy"]
    Apelin_Receptor_Modulation_The -->|"related to"| Apelin_Receptor_Modulation_The
    style Apelin_Receptor_Modulation_The fill:#81c784,stroke:#333,color:#000
    Apelin_Receptor_Modulation_The["table"]
    Apelin_Receptor_Modulation_The -->|"related to"| Apelin_Receptor_Modulation_The
    style Apelin_Receptor_Modulation_The fill:#81c784,stroke:#333,color:#000
    Apelin_Receptor_Modulation_The["class"]
    Apelin_Receptor_Modulation_The -->|"related to"| Apelin_Receptor_Modulation_The
    style Apelin_Receptor_Modulation_The fill:#81c784,stroke:#333,color:#000
    style Apelin_Receptor_Modulation_The fill:#4fc3f7,stroke:#333,color:#000

<table class=“infobox infobox-therapeutic”> <tr> <th class=“infobox-header” colspan=“2”>Apelin Receptor Modulation Therapy</th> </tr> <tr> <td class=“label”>Peptide</td> <td>Amino Acids</td> </tr> <tr> <td class=“label”>Apelin-36</td> <td>36</td> </tr> <tr> <td class=“label”>Apelin-16</td> <td>16</td> </tr> <tr> <td class=“label”>Apelin-13</td> <td>13</td> </tr> <tr> <td class=“label”>Apelin-12</td> <td>12</td> </tr> <tr> <td class=“label”>Effect</td> <td>Mechanism</td> </tr> <tr> <td class=“label”>Amyloid Reduction</td> <td>Enhanced autophagy</td> </tr> <tr> <td class=“label”>Tau Modification</td> <td>GSK-3beta inhibition</td> </tr> <tr> <td class=“label”>Synaptic Protection</td> <td>CREB/BDNF</td> </tr> <tr> <td class=“label”>Cognitive Improvement</td> <td>Multiple</td> </tr> <tr> <td class=“label”>Compound</td> <td>Type</td> </tr> <tr> <td class=“label”>Apelin-13</td> <td>Peptide</td> </tr> <tr> <td class=“label”>[Pyr^1]-Apelin-13</td> <td>Peptide</td> </tr> <tr> <td class=“label”>Small Molecule Agonists</td> <td>Small molecule</td> </tr> <tr> <td class=“label”>AAV-APJ</td> <td>Gene therapy</td> </tr> <tr> <td class=“label”>Strategy</td> <td>Approach</td> </tr> <tr> <td class=“label”>Intranasal</td> <td>Direct to CNS</td> </tr> <tr> <td class=“label”>AAV Vector</td> <td>Gene delivery</td> </tr> <tr> <td class=“label”>Exosomes</td> <td>Cell-derived</td> </tr> <tr> <td class=“label”>Small Molecule</td> <td>Oral delivery</td> </tr> </table>

Apelin receptor modulation represents an emerging therapeutic strategy for neurodegenerative diseases. The apelin-APJ system is a pleiotropic signaling pathway that influences multiple processes critical to neurodegeneration, including autophagy, blood-brain barrier (BBB) integrity, neuroinflammation, mitochondrial function, and neuronal survival[“@obrien2012”][@cook2014].

Apelin is a family of bioactive peptides (apelin-12, apelin-13, apelin-16, apelin-36) that signal through the APJ receptor (APLNR), a G protein-coupled receptor widely expressed in the central nervous system. The apelin-APJ axis has been implicated in the pathogenesis of Alzheimer’s disease, Parkinson’s disease, Amyotrophic Lateral Sclerosis, and atypical parkinsonian disorders including corticobasal syndrome and progressive supranuclear palsy.

The Apelin-APJ System

Apelin Peptides

The apelin precursor is a 77-amino acid preproprotein that is cleaved to generate various active fragments:

Apelin-13 and its stable analog [Pyr^1]-apelin-13 are the most studied for therapeutic applications due to their high receptor affinity and stability.

APJ Receptor (APLNR)

The APJ receptor is a Class A GPCR that:

  • Couples to multiple G proteins (Gαi/o, Gαq)
  • Activates PI3K/AKT, MAPK/ERK, and AMPK pathways
  • Undergoes ligand-dependent and independent (constitutive) signaling
  • Dimerizes with other receptors (e.g., angiotensin AT1 receptor)

Mechanisms of Neuroprotection

Autophagy Enhancement

Apelin-13 promotes autophagy through AMPK and mTOR signaling pathways[@tang2019]:

  1. AMPK Activation: Phosphorylates AMPK, enhancing TFEB nuclear translocation
  2. mTOR Inhibition: Reduces mTORC1 activity, relieving autophagy suppression
  3. Autophagosome Formation: Increases LC3-II conversion and autophagosome numbers
  4. Lysosomal Function: Enhances lysosomal biogenesis and function

This autophagy enhancement is particularly relevant for:

  • Alzheimer’s Disease: Clearing amyloid-beta and tau aggregates
  • Parkinson’s Disease: Removing alpha-synuclein aggregates
  • ALS: Degrading TDP-43 and SOD1 aggregates

Blood-Brain Barrier Protection

Apelin-13 protects BBB integrity through multiple mechanisms[@lu2018]:

  • Tight Junction Preservation: Maintains claudin-5 and ZO-1 expression
  • Endothelial Survival: Promotes endothelial cell survival via AKT
  • Reduced Permeability: Decreases BBB leakage in injury models
  • Angiogenesis Regulation: Modulates new vessel formation

BBB protection is critical for:

  • Limiting neurotoxin entry into the CNS
  • Maintaining CNS immune privilege
  • Ensuring proper drug delivery

Neuroinflammation Modulation

Apelin modulates neuroinflammation through[@chen2024]:

  1. Microglial Polarization: Shifts microglia toward anti-inflammatory (M2) phenotype
  2. Cytokine Reduction: Decreases TNF-α, IL-1β, IL-6 production
  3. NF-κB Inhibition: Reduces pro-inflammatory signaling
  4. T Cell Regulation: Modulates CNS immune responses

Mitochondrial Protection

Apelin-13 promotes mitochondrial health:

  • Biogenesis: Increases PGC-1α expression and mitochondrial replication
  • Fusion: Enhances Mfn1/2 and OPA1-mediated fusion
  • Mitophagy: Facilitates PINK1/Parkin-independent mitophagy
  • ATP Production: Improves mitochondrial respiration

Neuronal Survival

Neuroprotective signaling through:

  • AKT Pathway: Phosphorylation of AKT and downstream targets (GSK-3β, BAD)
  • ERK Pathway: Activation promotes neuronal survival
  • CREB Activation: Enhances BDNF expression and synaptic plasticity
  • Calcium Regulation: Modulates calcium homeostasis

Role in Specific Diseases

Alzheimer’s Disease

Apelin-13 has multiple beneficial effects in AD models[@xu2016][@wang2023]:

Parkinson’s Disease

Apelin-13 shows neuroprotection in PD models[@yang2017]:

  • Dopaminergic Protection: Preserves tyrosine hydroxylase neurons
  • Mitochondrial Rescue: Improves complex I function
  • Motor Improvement: Reduces akinesia in MPTP models
  • Alpha-Syn Clearance: Autophagy enhancement

Amyotrophic Lateral Sclerosis

In ALS models, apelin shows[@jiang2018]:

  • Motor Neuron Protection: Reduces motor neuron loss
  • Glial Modulation: Affects astrocyte and microglial reactivity
  • SOD1 Clearance: Enhances mutant SOD1 removal
  • Extended Survival: Improves lifespan in transgenic models

CBS/PSP (4R-Tauopathies)

Apelin modulation may benefit 4R-tauopathies:

  • Tau Clearance: Autophagy enhancement aids tau removal
  • BBB Protection: Important for brainstem regions affected in PSP
  • Neuroinflammation: Reduces tau-induced inflammation

Therapeutic Approaches

Apelin Receptor Agonists

Apelin Peptide Analogs

Modified analogs under development:

  • PEGylated apelin: Extended half-life
  • D-amino acid analogs: Protease resistance
  • Small peptide fragments: Blood-brain barrier penetration

Clinical Trials

Currently limited clinical trial data for CNS applications:

  1. (TBD): Apelin infusion in heart failure (not CNS)
  2. (TBD): APJ agonist in pulmonary hypertension
  3. No registered trials for neurodegenerative indications

Challenges

  • BBB Penetration: Apelin peptides do not cross BBB efficiently
  • Stability: Rapid degradation by proteases
  • Receptor Desensitization: Chronic exposure reduces signaling
  • Dose Timing: Optimal window for intervention unclear

Delivery Strategies

Cross-References

See Also

External Links

References

  1. O’Brien et al., Apelin-13 and apelin-36 in brain function (2012). Reviews apelin peptide functions in the CNS.

  2. Cook et al., Apelin and neurodegeneration (2014). Documents apelin’s role in neurodegenerative disease models.

  3. Xu et al., Apelin in Alzheimer’s disease (2016). Shows apelin-13 effects on amyloid pathology.

  4. Yang et al., Apelin-13 neuroprotection in Parkinson’s disease (2017). Demonstrates dopaminergic neuroprotection.

  5. Lu et al., Apelin-13 and blood-brain barrier (2018). Documents BBB protective effects.

  6. Jiang et al., Apelin in ALS (2018). Shows benefits in ALS models.

  7. Tang et al., Apelin-13 and autophagy in neurodegeneration (2019). Details autophagy enhancement mechanisms.

  8. Zhou et al., Apelin receptor agonists for neuroprotection (2021). Reviews therapeutic potential.

  9. Wang et al., Apelin-13 in tauopathy models (2023). Shows effects on tau pathology.

  10. Chen et al., Apelin receptor modulation and neuroinflammation (2024). Documents anti-inflammatory effects.

Related Hypotheses

From the SciDEX Exchange — scored by multi-agent debate

Related Analyses:

Sister wikis (recently updated · no domain on this page)

Recent activity here

No recent events touching this page.